Low Risk of Developing Inhibitors Found for Nuwiq Patients

Low Risk of Developing Inhibitors Found for Nuwiq Patients

287703

Low Risk of Developing Inhibitors Found for Nuwiq Patients

Treatment with Octapharma‘s Nuwiq is associated with a low risk of developing inhibitors — antibodies that prevent the medication from working properly — in previously untreated patients (PUPs) with hemophilia A, according to the results of a clinical trial. These findings were published in the journal Thrombosis and Haemostasis, in a study titled “Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.” Hemophilia A is caused by…

You must be logged in to read/download the full post.